Abiraterone acetate

General information

Abiraterone acetate is a potent inhibitor of cytochrome P450 C17 (CYPC17) [ ]. It is being used for the treatment of castration-resistant prostate cancer. It was first approved for use by the Food and Drug Administration (FDA) in April 2011 [ , ] and was approved for use in Europe by the European Medicine Agency (EMA) a few months later [ ].

Abiraterone selectively inhibits androgen biosynthesis in the adrenal glands, prostate tissue, and prostatic tumours by irreversibly blocking CYP17, which is involved in the production of testosterone.